Characterization of ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 for the Treatment of Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 2, p. s527, 2025. DOI: 10.25251/skin.10.supp.527. Disponível em: https://skin.dermsquared.com/skin/article/view/3295. Acesso em: 21 may. 2025.